JP2018510639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510639A5 JP2018510639A5 JP2017549766A JP2017549766A JP2018510639A5 JP 2018510639 A5 JP2018510639 A5 JP 2018510639A5 JP 2017549766 A JP2017549766 A JP 2017549766A JP 2017549766 A JP2017549766 A JP 2017549766A JP 2018510639 A5 JP2018510639 A5 JP 2018510639A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- item
- polypeptide
- nucleic acid
- multimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1504840.8 | 2015-03-23 | ||
| GBGB1504840.8A GB201504840D0 (en) | 2015-03-23 | 2015-03-23 | Chimeric antigen receptor |
| PCT/GB2016/050795 WO2016151315A1 (en) | 2015-03-23 | 2016-03-22 | Chimeric antigen receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001971A Division JP2020048588A (ja) | 2015-03-23 | 2020-01-09 | キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510639A JP2018510639A (ja) | 2018-04-19 |
| JP2018510639A5 true JP2018510639A5 (https=) | 2019-12-05 |
| JP6675417B2 JP6675417B2 (ja) | 2020-04-01 |
Family
ID=53052211
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549766A Expired - Fee Related JP6675417B2 (ja) | 2015-03-23 | 2016-03-22 | キメラ抗原受容体 |
| JP2020001971A Withdrawn JP2020048588A (ja) | 2015-03-23 | 2020-01-09 | キメラ抗原受容体 |
| JP2022201192A Withdrawn JP2023021396A (ja) | 2015-03-23 | 2022-12-16 | キメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001971A Withdrawn JP2020048588A (ja) | 2015-03-23 | 2020-01-09 | キメラ抗原受容体 |
| JP2022201192A Withdrawn JP2023021396A (ja) | 2015-03-23 | 2022-12-16 | キメラ抗原受容体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11058722B2 (https=) |
| EP (1) | EP3274366B8 (https=) |
| JP (3) | JP6675417B2 (https=) |
| KR (1) | KR102174280B1 (https=) |
| CN (1) | CN107406518B (https=) |
| AU (1) | AU2016238583B2 (https=) |
| BR (1) | BR112017018252A2 (https=) |
| CA (1) | CA2978852C (https=) |
| CL (1) | CL2017002413A1 (https=) |
| DK (1) | DK3274366T3 (https=) |
| ES (1) | ES2773527T3 (https=) |
| GB (1) | GB201504840D0 (https=) |
| HU (1) | HUE047929T2 (https=) |
| IL (1) | IL254254B (https=) |
| MX (1) | MX371384B (https=) |
| PL (1) | PL3274366T3 (https=) |
| PT (1) | PT3274366T (https=) |
| RU (1) | RU2752880C2 (https=) |
| SG (1) | SG11201706940QA (https=) |
| WO (1) | WO2016151315A1 (https=) |
| ZA (1) | ZA201705682B (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| US11982673B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201501936D0 (en) * | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| WO2018176144A1 (en) * | 2017-03-29 | 2018-10-04 | Sunnybrook Research Institute | Engineered t-cell modulating molecules and methods of using same |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| WO2019086394A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | The compbody - a multivalent target binder |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| WO2019220109A1 (en) | 2018-05-15 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
| EP3836944A4 (en) * | 2018-08-16 | 2022-05-11 | Memorial Sloan Kettering Cancer Center | LEUCINE ZIPPER BASED COMPOSITIONS AND METHODS OF USE |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CN109265550B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Bcma抗体、嵌合抗原受体和药物 |
| IL281428B2 (en) | 2018-09-27 | 2024-10-01 | Autolus Ltd | Chimeric antigen receptor |
| WO2020070290A1 (en) * | 2018-10-05 | 2020-04-09 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| EP3860642A1 (en) * | 2018-10-05 | 2021-08-11 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| GB201817822D0 (en) | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| JP7812549B2 (ja) * | 2019-02-21 | 2026-02-10 | アーベル リミテッド | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
| CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
| GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202017649D0 (en) | 2020-11-09 | 2020-12-23 | Autolus Ltd | Polypeptide |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| WO2022204326A1 (en) * | 2021-03-24 | 2022-09-29 | The Regents Of The University Of California | Humanized synthetic notch receptors with augmented transactivation domains and uses thereof |
| GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| WO2024019961A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cd2 recruiting chimeric antigen receptors and fusion proteins |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| WO2010102518A1 (zh) | 2009-03-13 | 2010-09-16 | 北京表源生物技术有限公司 | 一种融合蛋白多聚体 |
| KR101156085B1 (ko) * | 2010-01-29 | 2012-06-20 | 국립암센터 | ４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도 |
| US10745467B2 (en) * | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| WO2013051718A1 (ja) * | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| BR112014029417B1 (pt) * | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| MX367730B (es) | 2012-09-04 | 2019-09-04 | Cellectis | Receptor de antigeno quimerico multi-cadena y usos del mismo. |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
| NZ759969A (en) * | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| CN113307880B (zh) | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
-
2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
-
2016
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en not_active Ceased
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/ru active
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/pt not_active IP Right Cessation
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/ja not_active Expired - Fee Related
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/ko active Active
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/zh not_active Expired - Fee Related
- 2016-03-22 PL PL16712424T patent/PL3274366T3/pl unknown
- 2016-03-22 ES ES16712424T patent/ES2773527T3/es active Active
- 2016-03-22 MX MX2017010552A patent/MX371384B/es active IP Right Grant
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en not_active Ceased
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/da active
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/hu unknown
- 2016-03-22 PT PT167124247T patent/PT3274366T/pt unknown
-
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/en active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/es unknown
-
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/ja not_active Withdrawn
-
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510639A5 (https=) | ||
| RU2017132978A (ru) | Химерный рецептор антигена | |
| JP2020517287A5 (https=) | ||
| CN112074532B (zh) | 结合非天然NKG2D受体的非天然NKG2D配体的修饰的α1-α2结构域 | |
| JP6853250B2 (ja) | 抗体の挿入可能な可変フラグメント及びｎｋｇ２ｄリガンドの改変されたａ１−ａ２ドメイン、及び非天然のｎｋｇ２ｄ受容体に結合する非天然のｎｋｇ２ｄリガンド | |
| JP2022109953A5 (https=) | ||
| JP2020517294A5 (https=) | ||
| JP2019150066A5 (https=) | ||
| JP2018529380A5 (https=) | ||
| JP2020500510A5 (https=) | ||
| JP2017526361A5 (https=) | ||
| JP2018518540A5 (https=) | ||
| JP2020529841A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| JP2016536322A5 (https=) | ||
| JP2014158485A5 (https=) | ||
| JP2017529067A5 (https=) | ||
| JP2018518459A5 (https=) | ||
| JP2018523484A5 (https=) | ||
| CN111094333A (zh) | 异源二聚化的Ig结构域 | |
| CA2497496A1 (en) | In vitro peptide expression library | |
| JP2017534296A5 (https=) | ||
| JP2018528786A5 (https=) | ||
| CA3140064A1 (en) | Lockr-mediated recruitment of car t cells | |
| Zhu et al. | COMBODY: one‐domain antibody multimer with improved avidity |